MAIA Biotechnology Reports 90.5% Disease Control Rate in Third-Line NSCLC from THIO-101 Part C Expansion Trial

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, reported positive initial efficacy data on July 8, 2026 from Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine in third-line advanced non-small cell lung cancer. The interim data show a 90.5% disease control rate across 21 efficacy-evaluable patients—roughly triple the approximately 25–35% DCR reported for standard chemotherapy in this setting. Notably, Part C enrolled a more heavily pre-treated population than prior trial parts, making the consistency of the signal particularly meaningful.

Third-Line NSCLC Represents One of the Most Difficult-to-Treat Patient Populations

Non-small cell lung cancer is the most common form of lung cancer and accounts for the majority of lung cancer deaths globally. Patients who progress to the third line of therapy have already exhausted first-line checkpoint inhibitor regimens and at least one subsequent chemotherapy, including docetaxel. In that population, standard of care delivers a median overall survival of just 5.8 months. Disease control rates for available chemotherapies sit between 25% and 35%. Progression-free survival on standard regimens averages roughly 2.5 months. These grim benchmarks define the bar ateganosine needs to clear—and the early Part C data suggest it does so by a substantial margin.

Ateganosine Attacks Cancer Through Telomeres Rather Than Surface Receptors

Most oncology drugs target proteins on the surface of cancer cells or block specific signaling pathways. Ateganosine works differently. It is a modified nucleotide that exploits telomerase—the enzyme cancer cells rely on to maintain their telomeres and survive indefinitely. Once incorporated into telomeric DNA via telomerase, ateganosine induces targeted DNA damage responses and selective cancer cell death. The resulting telomeric fragments accumulate in cytosolic micronuclei and activate both innate immune responses through the cGAS/STING pathway and adaptive T-cell responses. That dual activation is why MAIA sequences ateganosine before cemiplimab: the telomeric damage primes the immune system, and the checkpoint inhibitor then sustains and amplifies the response. In preclinical models, this sequential regimen produced profound and persistent tumor regression, including cancer-type-specific immune memory.

Part C Data Holds Up Against a Harder Patient Population

The 90.5% interim DCR in Part C carries added weight because of who was enrolled. Every Part C patient had previously received docetaxel in addition to demonstrating resistance to both checkpoint inhibitors and other chemotherapies—a more exhausted immune and treatment history than participants in Parts A and B of THIO-101. Despite that, the Part C DCR of 90.5% aligns closely with the 88% DCR reported for third-line patients in Parts A and B. That consistency across a heavier pre-treatment burden suggests the ateganosine-cemiplimab regimen is not simply picking off easier-to-treat patients. MAIA has also completed international enrollment in Part C, which enrolled up to 48 participants across sites in Asia and Europe, giving the full dataset a broader and more diverse patient base than the earlier parts of the trial.

Survival Data From Parts A and B Underscores the Long-Term Potential

Beyond the DCR headline, survival data from Parts A and B of THIO-101—which together treated 79 patients—add important long-term context. As of March 2026, eight patients had achieved overall survival beyond two years without receiving subsequent lines of therapy. Among them, one third-line patient reached 33 months of survival against an expected median of 5.8 months. Four patients surpassed 30 months of survival, a benchmark MAIA describes as exceeding all known standards for advanced NSCLC treatment in this setting. Furthermore, progression-free survival in THIO-101 was 5.6 months as of September 2025—more than double the 2.5-month standard of care PFS. These are small-patient observations and carry the caveats of early trial data, but the durability pattern across multiple patients is difficult to dismiss.

Phase 3 THIO-104 Is Already Underway, and Fast Track Designation Smooths the Path

MAIA is not waiting for complete Phase 2 data to advance its program. The company dosed its first patient in the THIO-104 Phase 3 pivotal trial in December 2025, a milestone that reflects management’s confidence in the clinical signal accumulated across Parts A, B, and now C of THIO-101. THIO-104 also activated its first U.S. site in April 2026, extending recruitment beyond the international footprint. The FDA Fast Track designation ateganosine holds for advanced NSCLC further accelerates the development timeline: drugs that qualify for Fast Track and subsequently meet eligibility criteria become candidates for Accelerated Approval and Priority Review, the latter shortening the FDA’s standard review window to six months. Together, these factors position MAIA to move from Phase 2 confirmation toward a regulatory submission faster than a typical oncology program would allow.

Strategic Investment Summary

• Data Release: MAIA Biotechnology (NYSE American: MAIA) reported a 90.5% interim disease control rate in 21 efficacy-evaluable third-line NSCLC patients from its Phase 2 THIO-101 Part C expansion trial on July 8, 2026.
• Standard of Care Comparison: The 90.5% DCR is roughly triple the 25–35% disease control rate delivered by standard chemotherapy in third-line NSCLC, the most relevant efficacy benchmark in this setting.
• Heavier Pre-Treatment Population: Part C required all patients to have previously received docetaxel and demonstrated resistance to checkpoint inhibitors and other chemotherapies, a more exhausted population than Parts A and B—making the consistent DCR signal more compelling.
• Mechanism of Action: Ateganosine exploits telomerase to induce targeted telomeric DNA damage in cancer cells, activating both innate (cGAS/STING) and adaptive (T-cell) immune responses that are then amplified by sequential cemiplimab dosing.
• Survival Durability: Parts A and B of THIO-101 (79 patients) produced overall survival beyond two years in eight patients, including one third-line patient surviving 33 months against a median expectation of 5.8 months.
• Phase 3 Underway: MAIA dosed its first THIO-104 Phase 3 patient in December 2025 and activated its first U.S. site in April 2026, running the pivotal trial in parallel with the ongoing Phase 2 Part C data collection.
• Regulatory Tailwinds: FDA Fast Track designation for ateganosine in advanced NSCLC makes the drug eligible for Accelerated Approval and Priority Review, with the latter reducing the FDA’s standard review timeline to six months if eligibility criteria are met.

Find out more about the latest clinical updates and financial reports at the MAIA Biotechnology investor portal.